Atossa Genetics Launches FullCYTE Breast Aspirator in US; Two Leading Healthcare Providers have Placed Orders

Atossa Genetics Inc.

, announced today that it has launched the FullCYTE Breast Aspirator in the United States. Dr. Steven Quay, Chairman, CEO & President of Atossa Genetics, commented, "Launching and commercializing the FullCYTE device in the U.S. is one of our key objectives for 2015 and we are pleased to announce that we have taken significant steps forward in achieving this goal. Our contract manufacturer has produced an initial inventory of FullCYTE Breast Aspirators. Two leading healthcare providers have placed orders which are now being processed by our national distributors." Dr. Quay continued: "Atossa is focused on four key objectives in 2015 for the benefit of all of our stakeholders, especially women with serious breast disease: Launching and commercializing the FullCYTE Breast Aspirator in the U.S. market; Launching and commercializing the CE-marked ForeCYTE Breast Aspirator in the EU, and other non-U.S. markets Achieving top-line combined gross revenue of $8.0 million from medical device sales and laboratory services, including our pharmacogenomics test offering, and; Initiating pharmaceutical clinical trials in women for the treatment of serious breast diseases via local delivery of pharmaceuticals, potentially reducing systemic adverse events. We recently launched our ForeCYTE Breast Aspirator in the EU and now launching the FullCYTE Breast Aspirator in the U.S. significantly advances our key objectives. We look forward to announcing additional progress on each of these important objectives over the coming months."